secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055652
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector Q1 net loss $36.1M ($0.38/share); cash runway through 2026
------------------------------------------------------------------

- Q1 net loss $36.1M ($0.38/share) vs $45.9M ($0.55) in Q1 2023.
- Collaboration revenue $15.9M, roughly flat vs $16.5M year ago.
- Cash, equivalents & investments $562.1M; expects runway through 2026.
- INVOKE-2 Phase 2 TREM2 data for early Alzheimer's expected Q4 2024; INFRONT-3 Phase 3 latozinemab fully enrolled.
- Neil Berkley named CBO; Errol De Souza and Mark Altmeyer join Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017024055652/0000950170-24-055652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017024055652/alec-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer